Requests for medical information should be addressed to[email protected]
Adverse events should be reported to[email protected]
If you have any questions or comments, pleasecontact us

This email is intended for Israel healthcare professionals and other relevant decision makers only.

Please do not reply to this message as this is an inactive mailbox and your message will be automatically deleted. About your privacy: GSK may monitor our technology tools and services (including email, phone and other communications sent to and from GSK) in order to maintain the security of our systems and to protect our staff, customers and business partners from cyber threats and loss of information. Examples of these monitoring activities include checks for offensive materials, viruses and other malignant codes and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you and how we use your informationhere.
You can also view our websiteterms of use.
Trademarks are owned by or licensed to the GSK Group of Companies
Copyright © GlaxoSmithKline 2020. All rights reserved.
GlaxoSmithKline Limited, Registered in Israel.
Registered office: 25 Basel street, P.O. Box 3345, Petach-Tikva 4951038 Israel

May 2020 PM-IL-BEX-EML-200008